Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2019 07:00 ET | Source: Zafgen, Inc.

Zafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development

BOSTON, March 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
January 17, 2019 07:00 ET | Source: Zafgen, Inc.

Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061

Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg dose...
November 26, 2018 07:00 ET | Source: Zafgen, Inc.

Zafgen Provides Update on Investigational New Drug Application for ZGN-1061

BOSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
November 21, 2018 16:05 ET | Source: Zafgen, Inc.

Zafgen to Present at the 30th Annual Piper Jaffray Healthcare Conference

BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
November 07, 2018 16:05 ET | Source: Zafgen, Inc.

Zafgen Reports Third Quarter 2018 Operating and Financial Results

ZGN-1061 1.8 mg cohort for the Phase 2 proof-of-concept trial now fully enrolled; on track for topline results early 2019 ZGN-1258 nonclinical safety and efficacy data sets presented at Foundation...
November 06, 2018 16:05 ET | Source: Zafgen, Inc.

Zafgen to Present at the Stifel 2018 Healthcare Conference

BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
November 01, 2018 08:00 ET | Source: Zafgen, Inc.

Zafgen to Host Conference Call to Discuss Third Quarter 2018 Financial Results

BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
October 04, 2018 07:00 ET | Source: Zafgen, Inc.

Zafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference

Nonclinical data for ZGN-1258 reproduce efficacy seen in first generation candidate for PWS Data show highly improved safety profile Company also presenting study design of PATH for PWS natural...
August 08, 2018 16:05 ET | Source: Zafgen, Inc.

Zafgen to Present at the Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
August 07, 2018 16:05 ET | Source: Zafgen, Inc.

Zafgen Reports Second Quarter 2018 Operating and Financial Results

Phase 1 clinical trial for ZGN-1258 for Prader-Willi syndrome (PWS) expected to begin in the fourth quarter 2018 Multiple ZGN-1258 nonclinical studies accepted for presentation at upcoming Foundation...